The FDA has approved eflornithine to prevent relapse after standard-of-care therapy for neuroblastoma. The U.S. Food and Drug Administration (FDA) has approved eflornithine (Iwilfin) to reduce the risk of relapse in adult and pediatric...
The FDA has approved pirtobrutinib for patients with heavily pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca) for the treatment...
The FDA has approved nirogacestat for the treatment of noncancerous but painful growths called desmoid tumors. The U.S. Food and Drug Administration (FDA) has approved nirogacestat (Ogsiveo) for adult patients with desmoid tumors that...
The FDA has approved enzalutamide for non-metastatic prostate cancer that is sensitive to antiandrogen therapy. The U.S. Food and Drug Administration (FDA) has approved enzalutamide (Xtandi) for the treatment of non-metastatic castration-sensitive prostate cancer...
The FDA has approved capivasertib for the treatment of breast cancers with certain mutations. The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap), in combination with fulvestrant (Faslodex), for the treatment of...
The FDA has approved pembrolizumab for the first-line treatment of certain HER2-negative gastric and gastroesophageal junction cancers. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), in combination with a chemotherapy regimen...
The FDA has approved repotrectinib for certain patients with non-small cell lung cancer harboring a ROS1 mutation or rearrangement. The U.S. Food and Drug Administration (FDA) has approved repotrectinib (Augtyro) for the treatment of...
The FDA has approved another inhibitor of the VEGF receptor family for patients with metastatic, heavily pretreated colorectal cancer. The U.S. Food and Drug Administration (FDA) has approved fruquintinib (Fruzaqla) for adult patients with...
The FDA has approved the immune checkpoint inhibitor pembrolizumab for certain advanced cancers of the biliary tract. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), in combination with gemcitabine (Gemzar) and...
The FDA has approved the immune checkpoint inhibitor toripalimab for some patients with nasopharyngeal carcinoma. The U.S. Food and Drug Administration (FDA) has approved toripalimab-tpzi (Loqtorzi), in combination with the chemotherapies gemcitabine (Gemzar) and...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now